Back to Stock Dashboard
Sector:
Healthcare
Add to portfolio
MGX
Metagenomi Therapeutics, Inc.
CAPPED RATING
Metagenomi Therapeutics, Inc. (MGX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B); its weakest is Momentum (D).
Quantitative Factor Evaluation • Updated
Overall Rating
2.3
/ 5.0
C
Value
B
Factor Score
3.4
/ 5.0
Growth
C-
Factor Score
2.1
/ 5.0
Profitability
C-
Factor Score
2.1
/ 5.0
Momentum
D
Factor Score
1.4
/ 5.0
Revisions
C+
Factor Score
2.6
/ 5.0
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
P/E Ratio
-0.4
EV / EBITDA
0.4
Rev Growth YoY
-74.8%
Gross Margin
0.0%
Price Return 3M
-42.0%
Price Return 12M
-67.5%
Catalyst Signal
0.00
Market Cap
$27.0M
TTM Revenue
$7.1M
Price / Sales
3.8
ROE
-69.4%
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-13 | B (3.4) | C- (2.1) | C- (2.1) | D (1.4) | C+ (2.6) | C (2.3) |
| 2026-11-06 | B (3.4) | B- (3.0) | C (2.4) | D+ (1.5) | C+ (2.7) | C+ (2.6) |
| 2026-10-30 | B (3.3) | B- (2.9) | C+ (2.5) | D+ (1.7) | C+ (2.7) | C+ (2.6) |
| 2026-10-23 | B (3.3) | B- (2.9) | C+ (2.5) | D+ (1.6) | C+ (2.6) | C+ (2.6) |
| 2026-10-16 | B (3.4) | B- (3.0) | C+ (2.5) | D+ (1.7) | C+ (2.6) | C+ (2.6) |
Page
1
of
4